About: Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 April 1998

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у квітні 1998 (uk) article scientifique publié en 1998 (fr) im April 1998 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'abril de 1998 (ast) scientific article published on 01 April 1998 (en)
publication date	wds:Q74507662-74C9C95E-9D25-4C27-884C-D1AFE863EC40
publication date	1998-04-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q74507662-B3778B8C-FA86-4EFE-B126-6969907BABA8
language of work or name	English
author name string	wds:Q74507662-1B5FC257-56B5-44D7-99E5-BF3593C3429B wds:Q74507662-27B6EC60-2850-4AF3-9630-034ACF3EA05B wds:Q74507662-302C6253-EF9F-4E44-B749-E032BE2A19CA wds:Q74507662-3F2AD9D0-12C6-4822-8999-0A6EF602D750 wds:Q74507662-62BAF5E3-2ED7-4964-9A31-9AA57D3E37F3 wds:Q74507662-87DFCCB0-5173-4DEF-9603-173457351107 wds:Q74507662-A3D89B9A-2C81-4186-832F-005E144B2877 wds:Q74507662-B0D15824-22A2-43A4-B8CC-14E1B0686836 wds:Q74507662-B5B8F55D-34EA-4AC1-91F1-0CC4A65E02DD wds:Q74507662-CEB68FE5-8AFE-44BC-99FE-E1D5C5E05A3F
author name string	P Sharp A N Nicolaides S Mahmood M D Feher R S Elkeles W Richmond C Poulter J R Diamond S Dhanjil H Mather
rdfs:label	Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study (en) Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study (nl)
skos:prefLabel	Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study (en) Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study (nl)
name	Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study (en) Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study (nl)
title	wds:Q74507662-FC73CD56-21E2-4DD6-BF9B-A93A3014659C
title	Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study (en)
page(s)	wds:Q74507662-26EB2AEC-3D03-4B8D-9C51-51BE44F0B404
page(s)	641-648
instance of	wds:Q74507662-A3B86138-88D0-4CE7-B3AD-338819A77C18
instance of	scholarly article
main subject	wds:Q74507662-19E895A6-EB9B-45EB-8CFB-B00A83A817C1 wds:Q74507662-1A74E616-785E-43B4-AC4F-3A03AA0AE19D wds:Q74507662-4E96F9D6-B839-46E7-98E3-A3CCD33D1124 wds:Q74507662-A33B0135-61FF-4B86-91AD-7B44FD1BEC30 wds:Q74507662-ACC47418-D4D6-4846-802A-88C468806D50
main subject	prevention cardiovascular disease placebo type 2 diabetes disease prevention
PubMed ID	wds:Q74507662-659F9641-DAA5-4EF4-BB5B-92F2AD6F05DE
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9571357
PubMed ID	9571357
published in	wds:Q74507662-0C43F0FA-22F4-42B2-BDE1-09C189D9863F
published in	Diabetes Care
issue	wds:Q74507662-B1EB41FA-678D-496D-8265-594071367F3C
volume	wds:Q74507662-04A5D324-E926-4FEA-A6DC-51DE2F8AB311
issue	4
volume	21
DOI	wds:Q74507662-778D291E-B3AE-4F27-9A67-44BF5F43030E
DOI	http://dx.doi.org/10.2337/DIACARE.21.4.641
DOI	10.2337/DIACARE.21.4.641
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q74507662
is cites work of	Statins and fibrates for preventing melanoma Diabetes, hyperlipidemia, and coronary artery disease Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Do persons with diabetes benefit from combination statin and fibrate therapy? "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study Baseline characteristics of the study population in the Diabetes Atherosclerosis Intervention Study (DAIS). World Health Organization Collaborating Centre for the Study of Atherosclerosis in Diabetes Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons Lipid-lowering drugs Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review Management of dyslipidemia in elderly diabetic patients. Update on the use of fibrates: focus on bezafibrate Diabetes: statins, fibrates, or both? Role of fibrates in the management of hypertriglyceridemia Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481] Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481] Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities PPAR Agonists and Cardiovascular Disease in Diabetes Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia Diabetes: managing dyslipidaemia Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats. Fibrates for secondary prevention of cardiovascular disease and stroke Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins Drugs affecting homocysteine metabolism: impact on cardiovascular risk

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software